Latest Headlines
-
Synthekine Announces U.S. FDA Clearance Of IND Application For CD19 CAR-T And Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, For Treatment Of Lupus Without Lymphodepletion
3/26/2024
Synthekine Inc., an engineered cytokine therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to evaluate SYNCAR-001 + STK-009, its orthogonal IL-2 and CD19 CAR-T combination therapy, in patients with non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN), without the use of any lymphodepletion.
-
CinFina Pharma Announces FDA Clearance Of Investigational New Drug Application And First Participants Dosed In Phase 1 Trial Of CIN-110 For The Treatment Of Obesity
3/26/2024
CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity and metabolic diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) for CIN-110, aPYY3-36analog, allowing the first in-human clinical study to proceed.
-
Researchers Devise New Method To Find Proteins For Targeted Treatment Of Disease
3/26/2024
Researchers at Sinai Health and the University of Toronto have created a new platform to identify proteins that can be used to control the stability of other proteins – a new and largely unrealized approach to treating diseases.
-
EPNextS Group And Frontage Laboratories, Inc. Announce Collaboration In Early Phase Clinical Trials In The United States To Improve ‘Drug Lag’ And ‘Drug Loss’ Issues In Japan
3/26/2024
EPNextS Group, a Japanese based leading provider of clinical trial solutions, and Frontage Laboratories, Inc., a US based full-service contract research organization (CRO), have announced a collaboration aimed at addressing the challenges of "Drug Lag" and "Drug Loss" in Japan.
-
Teva UK And Closed Loop Medicine Announce Strategic Partnership To Advance Development Of Personalised Medicines
3/26/2024
Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines.
-
Ubiquigent And Debiopharm Enter Agreement To Support USP1 Inhibitor Programme For Debio 0432
3/26/2024
Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases.
-
Safer, More Efficient Drug Discovery
3/26/2024
McGill researchers have discovered a safer and more efficient technique for testing new drugs while they are in development.
-
Amneal Receives U.S. FDA Approval For Ciprofloxacin And Dexamethasone Otic Suspension
3/25/2024
Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for ciprofloxacin and dexamethasone otic suspension.
-
Biocytogen Enters Collaboration With ABL Bio To Develop New Bispecific Antibody-Drug Conjugates
3/25/2024
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
-
Bio-Thera Solutions Receives IND Clearance From US FDA To Initiate A Phase II Study For BAT8006, An Innovative Antibody Drug Conjugate Targeting Folate Receptor α
3/25/2024
Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced receiving IND clearance from the US FDA for a phase II Study for BAT8006, an innovative Antibody Drug Conjugate (ADC) targeting Folate Receptor α (FRα).